⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5040245 | 0.98 | — | — | |
| SCHEMBL27907943 | 0.93 | — | — | |
| SCHEMBL11568727 | 0.75 | — | — | |
| SCHEMBL9747588 | 0.68 | — | — | |
| SCHEMBL6407543 | 0.66 | — | — | |
| SCHEMBL3417231 | 0.59 | — | — | |
| SCHEMBL15619220 | 0.57 | — | — | |
| SCHEMBL4913297 | 0.57 | — | — | |
| SCHEMBL27963552 | 0.53 | — | — | |
| SCHEMBL5197398 | 0.50 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 697 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277568-A1 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | ELEUSIS THERAPEUTICS US, INC. | 2023-09-07 | — | — | US | claimed |
| US-11154537-B2 | Method of treatment for ketamine infusion | ELEUSIS THERAPEUTICS US, INC. (US) | 2021-10-26 | — | — | US | claimed |
| US-20210322384-A1 | Method of Treatment for Ketamine Infusion | ELEUSIS THERAPEUTICS US, INC. (US) | 2021-10-21 | — | — | US | claimed |
| EP-3747358-A2 | USE OF ELECTRORETINOGRAPHY (ERG) FOR THE ASSESSMENT OF PSYCHIATRIC DISORDERS | Universite Laval (CA) | 2020-12-09 | — | — | EP | claimed |
| US-20200046683-A1 | METHOD OF TREATMENT FOR KETAMINE INFUSION | Beckley Psytech Limited (GB) | 2020-02-13 | — | — | US | claimed |
| US-9974839-B2 | Self-assembled toroidal-spiral particles and manufacture and uses thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-05-22 | — | — | US | claimed |
| US-20160029919-A1 | USE OF ELECTRORETINOGRAPHY (ERG) FOR THE ASSESSMENT OF PSYCHIATRIC DISORDERS | UNIVERSITE LAVAL (CA) | 2016-02-04 | — | — | US | claimed |
| EP-2956056-A1 | USE OF ELECTRORETINOGRAPHY (ERG) FOR THE ASSESSMENT OF PSYCHIATRIC DISORDERS | Université Laval (CA) | 2015-12-23 | — | — | EP | claimed |
| US-20150030686-A1 | SELF-ASSEMBLED TOROIDAL-SPIRAL PARTICLES AND MANUFACTURE AND USES THEREOF | UNIV ILLINOIS (US) | 2015-01-29 | — | — | US | claimed |
| WO-2014138987-A1 | USE OF ELECTRORETINOGRAPHY (ERG) FOR THE ASSESSMENT OF PSYCHIATRIC DISORDERS | UNIVERSITé LAVAL (CA) | 2014-09-18 | — | — | WO | claimed |
| US-7425627-B2 | Methods of synthesizing olanzapine | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-09-16 | — | — | US | claimed |
| EP-1884243-A1 | Use of an antipsychotic drug for the treatment of ALS-associated cachexia | Charité - Universitätsmedizin Berlin (DE) | 2008-02-06 | — | — | EP | claimed |
| WO-2007137224-A2 | METHOD OF TREATMENT | VANDA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007128442-A1 | USE OF AN ANTIPSYCHOTIC DRUG FOR THE TREATMENT OF ALS-ASSOCIATED CACHEXIA | Charité-Universitätsmedizin Berlin (DE) | 2007-11-15 | — | — | WO | claimed |
| JP-2007515428-A | — | — | 2007-06-14 | — | — | JP | claimed |
| CN-1906201-A | Method for synthesizing olanzapine | TEVA PHARMA (IL) | 2007-01-31 | — | — | CN | claimed |
| EP-1611139-A1 | METHODS OF PREPARING OLANZAPINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-01-04 | — | — | EP | claimed |
| US-20050159408-A1 | Methods of synthesizing olanzapine | TEVA PHARMACEUTICALS USA, INC. | 2005-07-21 | — | — | US | claimed |
| WO-2005063771-A1 | METHODS OF PREPARING OLANZAPINE | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2005-07-14 | — | — | WO | claimed |
| US-20260104418-A1 | CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCER | UNIV CALIFORNIA (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260048062-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF PSYCHOSIS AND PSYCHOTIC DISORDERS | OVID THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12533378-B2 | Treatment of adverse effects caused by atypical antipsychotics | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-01-27 | — | — | US | disclosed |
| US-20260007628-A1 | TREATMENT AND PREVENTION OF INFECTIONS USING VEGETABLE OIL-DERIVED POLYOLS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2026-01-08 | — | — | US | disclosed |
| US-12465576-B2 | Biotherapy for viral infections using biopolymer based micro/nanogels | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250333501-A1 | CLAUDIN 4 AND CLAUDIN 9 ANTIBODIES AND METHODS OF TREATING CANCER | UNIV CALIFORNIA (US) | 2025-10-30 | — | — | US | disclosed |
| EP-3747358-B1 | USE OF ELECTRORETINOGRAPHY (ERG) FOR THE ASSESSMENT OF PSYCHIATRIC DISORDERS | UNIV LAVAL (CA) | 2025-10-15 | — | — | EP | disclosed |
| US-12440467-B2 | Treatment and prevention of infections using vegetable oil-derived polyols | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250282870-A1 | CTLA4-BINDING PROTEINS AND METHODS OF TREATING CANCER | BIOENTRE LLC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250255830-A1 | BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2025-08-14 | — | — | US | disclosed |
| EP-4594294-A1 | DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250228955-A1 | PLATFORM TECHNOLOGY FOR BISPECIFIC ANTIGENBINDING PROTEINS | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-07-17 | — | — | US | disclosed |
| US-12357223-B2 | Use of electroretinography (ERG) for the assessment of psychiatric disorders | UNIVERSITé LAVAL (CA) | 2025-07-15 | — | — | US | disclosed |
| EP-3458477-B1 | ANTI-FACTOR IX PADUA ANTIBODIES | TAKEDA PHARMACEUTICALS CO (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-12345709-B2 | CLAUDIN18 antibodies and methods of treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025106822-A2 | P2RY8 ANTIBODIES AND METHODS OF TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-22 | — | — | WO | disclosed |
| US-12269900-B2 | Inhibitors of β integrin-G protein α subunit binding interactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-04-08 | — | — | US | disclosed |
| US-12263252-B2 | Biotherapy for viral infections using biopolymer based micro/nanogels | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2025-04-01 | — | — | US | disclosed |
| EP-4527408-A2 | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | The Regents of the University of California (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250073178-A1 | BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2025-03-06 | — | — | US | disclosed |
| US-20250073165-A1 | OLANZAPINE, COMPOSITIONS THEREOF AND METHODS OF USE THEREOF | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2025-03-06 | — | — | US | disclosed |
| US-20250073207-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | ELEUSIS THERAPEUTICS US, INC. | 2025-03-06 | — | — | US | disclosed |
| US-20250066469-A1 | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-02-27 | — | — | US | disclosed |
| US-20250051437-A1 | CDH17 ANTIBODIES AND METHODS OF TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-02-13 | — | — | US | disclosed |
| US-20250042992-A1 | DLK1 ANTIBODIES AND METHODS OF TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-02-06 | — | — | US | disclosed |
| US-20250000986-A1 | IMPROVED SOPHOROLIPID DERIVATIVES WITH THERAPEUTIC AGENT CARGOS AND THEIR USE | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2025-01-02 | — | — | US | disclosed |
| WO-2025006982-A1 | POTENT AND SELECTIVE DOPAMINE D3 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-01-02 | — | — | WO | disclosed |
| CN-111565744-B | Tight-junction protein 6 antibodies and methods of treating cancer | 加利福尼亚大学董事会 | 2024-12-31 | — | — | CN | disclosed |
| EP-3941946-B1 | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | UNIV CALIFORNIA (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-109563154-B | Anti-Parawatt factor IX antibodies | 武田药品工业株式会社 | 2024-12-13 | — | — | CN | disclosed |
| EP-4472669-A1 | IMPROVED SOPHOROLIPID DERIVATIVES WITH THERAPEUTIC AGENT CARGOS AND THEIR USE | Locus Solutions IPCO, LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240400674-A1 | CLAUDIN 4 AND CLAUDIN 9 ANTIBODIES AND METHODS OF TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-12-05 | — | — | US | disclosed |
| EP-4135721-B1 | TREATMENT OF ADVERSE EFFECTS CAUSED BY ATYPICAL ANTIPSYCHOTICS | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECH CO LTD (CN) | 2024-11-20 | — | — | EP | disclosed |
| EP-4463153-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | Eleusis Therapeutics US, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12144897-B2 | Biotherapy for viral infections using biopolymer based micro/nanogels | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4444349-A1 | CDH17 ANTIBODIES AND METHODS OF TREATING CANCER | The Regents of The University of California (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4444350-A1 | DLK1 ANTIBODIES AND METHODS OF TREATING CANCER | The Regents of The University of California (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4435009-A2 | CLAUDIN6 ANTIBODIES AND METHODS OF TREATING CANCER | The Regents of the University of California (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-118667021-A | Tight-junction protein 6 antibodies and methods of treating cancer | 加利福尼亚大学董事会 | 2024-09-20 | — | — | CN | disclosed |
| US-12065489-B2 | Claudin-6 antibodies and drug conjugates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-20 | — | — | US | disclosed |
| US-11999798-B2 | Anti-factor IX padua antibodies | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-04 | — | — | US | disclosed |
| EP-3826667-B1 | CLAUDIN6 ANTIBODIES AND METHODS OF TREATING CANCER | UNIV CALIFORNIA (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024072930-A1 | DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240033236-A1 | METHODS OF TREATING HERPES VIRAL INFECTION WITH 4-PHENYLBUTYRATE (PBA) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2024-02-01 | — | — | US | disclosed |
| WO-2023250380-A2 | PLATFORM TECHNOLOGY FOR BISPECIFIC ANTIGEN-BINDING PROTEINS | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023240287-A1 | COMBINATIONS OF CTLA4 BINDING PROTEINS AND METHODS OF TREATING CANCER | BIOENTRE LLC (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11834499-B1 | Claudin18 antibodies and methods of treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4281187-A1 | CTLA4-BINDING PROTEINS AND METHODS OF TREATING CANCER | Bioentre LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230277568-A1 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | ELEUSIS THERAPEUTICS US, INC. | 2023-09-07 | — | — | US | disclosed |
| EP-4228621-A1 | METHODS OF TREATING HERPES VIRAL INFECTION WITH 4-PHENYLBUTYRATE (PBA) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023150149-A1 | IMPROVED SOPHOROLIPID DERIVATIVES WITH THERAPEUTIC AGENT CARGOS AND THEIR USE | LOCUS SOLUTIONS IPCO, LLC (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023139531-A1 | OLANZAPINE, COMPOSITIONS THEREOF AND METHODS OF USE THEREOF | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023137094-A1 | PSILOCIN BENZOATE FORMULATION FOR INTRAVENOUS INFUSION | ELEUSIS THERAPEUTICS US, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023107560-A1 | DLK1 ANTIBODIES AND METHODS OF TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107558-A1 | CDH17 ANTIBODIES AND METHODS OF TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230181515-A1 | TREATMENT AND PREVENTION OF INFECTIONS USING VEGETABLE OIL-DERIVED POLYOLS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230158065-A1 | TREATMENT OF ADVERSE EFFECTS CAUSED BY ATYPICAL ANTIPSYCHOTICS | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4135721-A1 | TREATMENT OF ADVERSE EFFECTS CAUSED BY ATYPICAL ANTIPSYCHOTICS | Shenzhen Profound View Pharmaceutical Technology Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| US-20230049752-A1 | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-02-16 | — | — | US | disclosed |
| WO-2022246405-A1 | METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH MUSCARINIC RECEPTOR ACTIVATION AND ANTIPSYCHOTICS | Karuna Therapeutics, Inc. (US) | 2022-11-24 | — | — | WO | disclosed |
| US-20220370454-A1 | METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH MUSCARINIC RECEPTOR ACTIVATION AND ANTIPSYCHOTICS | Karuna Therapeutics, Inc. | 2022-11-24 | — | — | US | disclosed |
| US-20220372134-A1 | CLAUDIN6 ANTIBODIES AND METHODS OF TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-11-24 | — | — | US | disclosed |
| US-20220372133-A1 | CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-11-24 | — | — | US | disclosed |
| EP-4091607-A1 | METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH MUSCARINIC RECEPTOR ACTIVATOR XANOMELINE AND ANTIPSYCHOTICS | Karuna Therapeutics, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220313617-A1 | BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2022-10-06 | — | — | US | disclosed |
| WO-2022159575-A1 | CTLA4-BINDING PROTEINS AND METHODS OF TREATING CANCER | BIOENTRE LLC (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220177583-A1 | CLAUDIN-6 BISPECIFIC ANTIBODIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-09 | — | — | US | disclosed |
| US-20220160872-A1 | Drug Adsorbed Highly Porous Activated Carbon for Enhanced Drug Delivery | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2022-05-26 | — | — | US | disclosed |
| US-20220162299-A1 | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-26 | — | — | US | disclosed |
| EP-3999548-A1 | CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCER | The Regents of the University of California (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220133209-A1 | USE OF ELECTRORETINOGRAPHY (ERG) FOR THE ASSESSMENT OF PSYCHIATRIC DISORDERS | UNIVERSITE LAVAL (CA) | 2022-05-05 | — | — | US | disclosed |
| WO-2022081773-A1 | METHODS OF TREATING HERPES VIRAL INFECTION WITH 4-PHENYLBUTYRATE (PBA) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022082058-A1 | METHOD OF TREATMENT BY TRYPTAMINE ALKALOIDS | ELEUSIS THERAPEUTICS US, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| CN-114364701-A | Encapsulated protein 18 antibodies and methods of treating cancer | 加利福尼亚大学董事会 | 2022-04-15 | — | — | CN | disclosed |
| EP-3980041-A1 | BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-114288304-A | Anti-schizophrenia composition and application thereof | 江苏海洋大学 | 2022-04-08 | — | — | CN | disclosed |
| CN-114206934-A | Encapsulated protein-6 bispecific antibodies | 加利福尼亚大学董事会 | 2022-03-18 | — | — | CN | disclosed |
| CN-114173796-A | Biotherapeutic treatment of viral infections using biopolymer based micro/nanogels | 佛罗里达国际大学董事会 | 2022-03-11 | — | — | CN | disclosed |
| CN-114174340-A | Encapsulated protein-6 antibodies and drug conjugates | 加利福尼亚大学董事会 | 2022-03-11 | — | — | CN | disclosed |
| US-11259738-B2 | Use of electroretinography (ERG) for the assessment of psychiatric disorders | UNIVERSITé LAVAL (CA) | 2022-03-01 | — | — | US | disclosed |
| US-20220056150-A1 | ANTI-FACTOR IX PADUA ANTIBODIES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-24 | — | — | US | disclosed |
| EP-3952841-A1 | DRUG ADSORBED HIGHLY POROUS ACTIVATED CARBON FOR ENHANCED DRUG DELIVERY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3946357-A1 | TOPICAL FORMULATIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES | Winsantor, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3941946-A1 | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | The Regents of the University of California (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3941944-A1 | CLAUDIN-6 BISPECIFIC ANTIBODIES | The Regents of the University of California (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113811306-A | Topical formulations for the treatment of peripheral neuropathy | 温桑托尔公司 | 2021-12-17 | — | — | CN | disclosed |
| WO-2021226736-A1 | TREATMENT OF ADVERSE EFFECTS CAUSED BY ATYPICAL ANTIPSYCHOTICS | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2021-11-18 | — | — | WO | disclosed |
| US-11154537-B2 | Method of treatment for ketamine infusion | ELEUSIS THERAPEUTICS US, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210322384-A1 | Method of Treatment for Ketamine Infusion | ELEUSIS THERAPEUTICS US, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210205324-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT | BOEHRINGER INGELHEIM INT (DE) | 2021-07-08 | — | — | US | disclosed |
| EP-3826667-A2 | CLAUDIN6 ANTIBODIES AND METHODS OF TREATING CANCER | The Regents of the University of California (US) | 2021-06-02 | — | — | EP | disclosed |
| WO-2021011885-A9 | CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20210054026-A1 | Inhibitors of Beta Integrin-G Protein Alpha Subunit Binding Interactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2021-02-25 | — | — | US | disclosed |
| WO-2021011885-A1 | CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2020247730-A1 | BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-3747358-A2 | USE OF ELECTRORETINOGRAPHY (ERG) FOR THE ASSESSMENT OF PSYCHIATRIC DISORDERS | Universite Laval (CA) | 2020-12-09 | — | — | EP | disclosed |
| WO-2020210376-A1 | DRUG ADSORBED HIGHLY POROUS ACTIVATED CARBON FOR ENHANCED DRUG DELIVERY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20200316134-A1 | Biological Scaffold Comprising Therapeutic Cells | UNIVERSITY OF MIAMI | 2020-10-08 | — | — | US | disclosed |
| WO-2020198252-A1 | TOPICAL FORMULATIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES | WINSANTOR, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020191344-A1 | CLAUDIN-6 BISPECIFIC ANTIBODIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191342-A1 | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20200291111-A1 | CLAUDIN6 ANTIBODIES AND METHODS OF TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-09-17 | — | — | US | disclosed |
| CN-111565744-A | Claudin 6 antibodies and methods of treating cancer | 加利福尼亚大学董事会 | 2020-08-21 | — | — | CN | disclosed |
| US-20200254037-A1 | TREATMENT OF TRIPLE NEGATIVE BREAST CANCER OR COLORECTAL CANCER WITH LIVER METASTASES WITH AN ANTI PD-L1 ANTIBODY AND AN ONCOLYTIC VIRUS | AMGEN INC. | 2020-08-13 | — | — | US | disclosed |
| US-10738080-B2 | Inhibitors of beta integrin-G protein alpha subunit binding interactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3533393-B1 | USE OF ELECTRORETINOGRAPHY (ERG) FOR THE ASSESSMENT OF PSYCHIATRIC DISORDERS | UNIV LAVAL (CA) | 2020-07-22 | — | — | EP | disclosed |
| US-20200222423-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT | BOEHRINGER INGELHEIM INT (DE) | 2020-07-16 | — | — | US | disclosed |
| EP-3664844-A1 | TREATMENT OF TRIPLE NEGATIVE BREAST CANCER OR COLORECTAL CANCER WITH LIVER METASTASES WITH AN ANTI PD-L1 ANTIBODY AND AN ONCOLYTIC VIRUS | Amgen Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| CN-111246883-A | Treatment of triple negative breast cancer or colorectal cancer with anti-PD-L1 antibody and oncolytic virus with liver metastasis | 美国安进公司 | 2020-06-05 | — | — | CN | disclosed |
| US-10639382-B2 | Method for treating leukemia | NATIONAL GUARD HEALTH AFFAIRS (SA) | 2020-05-05 | — | — | US | disclosed |
| US-20200085338-A1 | USE OF ELECTRORETINOGRAPHY (ERG) FOR THE ASSESSMENT OF PSYCHIATRIC DISORDERS | UNIVERSITé LAVAL (CA) | 2020-03-19 | — | — | US | disclosed |
| EP-3191471-B1 | 4,5-DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2020-03-11 | — | — | EP | disclosed |
| US-20200046683-A1 | METHOD OF TREATMENT FOR KETAMINE INFUSION | Beckley Psytech Limited (GB) | 2020-02-13 | — | — | US | disclosed |
| EP-3600350-A1 | BIOLOGICAL SCAFFOLD COMPRISING THERAPEUTIC CELLS | University of Miami (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20190290632-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-09-26 | — | — | US | disclosed |
| US-20190290645-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-09-26 | — | — | US | disclosed |
| EP-3533393-A1 | USE OF ELECTRORETINOGRAPHY (ERG) FOR THE ASSESSMENT OF PSYCHIATRIC DISORDERS | Universite Laval (CA) | 2019-09-04 | — | — | EP | disclosed |
| US-10338052-B2 | Methods of detecting sulfur-containing compounds | VANDERBILT UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190194351-A1 | ANTI-FACTOR IX PADUA ANTIBODIES | BAXALTA INCORPORATED (US) | 2019-06-27 | — | — | US | disclosed |
| EP-2956056-B1 | ELECTRORETINOGRAPHY (ERG) SYSTEM FOR THE ASSESSMENT OF PSYCHIATRIC DISORDERS | UNIV LAVAL (CA) | 2019-06-05 | — | — | EP | disclosed |
| EP-3057958-B1 | AMINOTETRALINE AND AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-05-01 | — | — | EP | disclosed |
| EP-2970215-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-04-17 | — | — | EP | disclosed |
| EP-3458477-A1 | ANTI-FACTOR IX PADUA ANTIBODIES | Baxalta Incorporated (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2019056023-A2 | CLAUDIN6 ANTIBODIES AND METHODS OF TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019032431-A1 | TREATMENT OF TRIPLE NEGATIVE BREAST CANCER OR COLORECTAL CANCER WITH LIVER METASTASES WITH AN ANTI PD-L1 ANTIBODY AND AN ONCOLYTIC VIRUS | AMGEN INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| US-20190023740-A1 | INHIBITORS OF BETA INTEGRIN-G PROTEIN ALPHA SUBUNIT BINDING INTERACTIONS | UNIV ILLINOIS (US) | 2019-01-24 | — | — | US | disclosed |
| EP-2814810-B1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2018-12-19 | — | — | EP | disclosed |
| EP-2888269-B1 | HAPTENS OF OLANZAPINE | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-24 | — | — | EP | disclosed |
| US-20180296692-A1 | METHOD OF TREATING LEUKEMIA | NATIONAL GUARD HEALTH AFFAIRS (SA) | 2018-10-18 | — | — | US | disclosed |
| WO-2018183194-A1 | BIOLOGICAL SCAFFOLD COMPRISING THERAPEUTIC CELLS | UNIVERSITY OF MIAMI (US) | 2018-10-04 | — | — | WO | disclosed |
| EP-2714052-B1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS TREATED WITH NEUROLEPTIC AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2018-09-19 | — | — | EP | disclosed |
| EP-2959294-B1 | METHOD TO EVALUATE THE TISSUE TARGETING OF A MOLECULE OF INTEREST | IMABIOTECH (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-10011634-B2 | Inhibitors of beta integrin-G protein alpha subunit binding interactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180177794-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT | BOEHRINGER INGELHEIM INT (DE) | 2018-06-28 | — | — | US | disclosed |
| US-9974839-B2 | Self-assembled toroidal-spiral particles and manufacture and uses thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-05-22 | — | — | US | disclosed |
| US-9895549-B2 | On-demand drug release using magneto-electric nanoparticles | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-02-20 | — | — | US | disclosed |
| WO-2017200981-A1 | ANTI-FACTOR IX PADUA ANTIBODIES | BAXALTA INCORPORATED (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20170290916-A1 | Materials and Methods for the Delivery of a Nanocarrier to the Brain | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2017-10-12 | — | — | US | disclosed |
| US-9724503-B2 | On-demand drug release using magneto-electric nanoparticles | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3191471-A1 | 4,5-DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170173009-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170153218-A1 | METHODS OF DETECTING SULFUR-CONTAINING COMPOUNDS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-06-01 | — | — | US | disclosed |
| US-9656955-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9650334-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9645138-B2 | Method to evaluate the tissue targeting of a molecule of interest | IMABIOTECH (FR) | 2017-05-09 | — | — | US | disclosed |
| EP-2247284-B1 | PROCESS TO MINIMIZE POLYMORPHISM | SCHERER TECHNOLOGIES LLC R P (US) | 2017-04-19 | — | — | EP | disclosed |
| US-9586942-B2 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-07 | — | — | US | disclosed |
| US-9586945-B2 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-07 | — | — | US | disclosed |
| EP-2739614-B1 | AMINOCHROMANEs, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2017-02-22 | — | — | EP | disclosed |
| US-9550754-B2 | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-01-24 | — | — | US | disclosed |
| US-9539216-B2 | Multi-phase, multi-compartment, capsular delivery apparatus and methods for using same | INNERCAP TECHNOLOGIES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2328619-B1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | Baxalta GmbH (CH) | 2016-12-07 | — | — | EP | disclosed |
| US-20160257711-A1 | INHIBITORS OF BETA INTEGRIN-G PROTEIN ALPHA SUBUNIT BINDING INTERACTIONS | UNIV ILLINOIS (US) | 2016-09-08 | — | — | US | disclosed |
| US-9365512-B2 | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-06-14 | — | — | US | disclosed |
| EP-2396296-B1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-20160136100-A1 | MULTI-PHASE, MULTI-COMPARTMENT, CAPSULAR DELIVERY APPARATUS AND METHODS FOR USING SAME | INNERCAP TECHNOLOGIES, INC. | 2016-05-19 | — | — | US | disclosed |
| US-9309200-B2 | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-04-12 | — | — | US | disclosed |
| WO-2016038160-A1 | 4,5-DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-03-17 | — | — | WO | disclosed |
| US-20160075691-A1 | 4,5- DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-03-17 | — | — | US | disclosed |
| US-20160074415-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT | BOEHRINGER INGELHEIM INT (DE) | 2016-03-17 | — | — | US | disclosed |
| EP-2547359-B1 | INHIBITORS OF BETA INTEGRIN-G PROTEIN ALPHA SUBUNIT BINDING INTERACTIONS | UNIV ILLINOIS (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2655401-B1 | INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR-HEAT SHOCK PROTEIN 90 BINDING INTERACTION | UNIV MICHIGAN (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2375900-B1 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES | BIOVISTA INC (US) | 2016-03-02 | — | — | EP | disclosed |
| CN-103214414-B | The diamine derivative of opticity and manufacture method thereof | SANKYO CO. (JP) | 2016-02-17 | — | — | CN | disclosed |
| US-20160029919-A1 | USE OF ELECTRORETINOGRAPHY (ERG) FOR THE ASSESSMENT OF PSYCHIATRIC DISORDERS | UNIVERSITE LAVAL (CA) | 2016-02-04 | — | — | US | disclosed |
| US-20160030724-A1 | ON-DEMAND DRUG RELEASE USING MAGNETO-ELECTRIC NANOPARTICLES | LIANG PING (US) | 2016-02-04 | — | — | US | disclosed |
| US-9241911-B2 | Multi-phase, multi-compartment, capsular delivery apparatus and methods for using same | INNERCAP TECHNOLOGIES, INC. | 2016-01-26 | — | — | US | disclosed |
| EP-2970215-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | disclosed |
| US-9238619-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-19 | — | — | US | disclosed |
| US-9227930-B2 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150377862-A1 | METHOD TO EVALUATE THE TISSUE TARGETING OF A MOLECULE OF INTEREST | IMABIOTECH (FR) | 2015-12-31 | — | — | US | disclosed |
| EP-2959294-A1 | METHOD TO EVALUATE THE TISSUE TARGETING OF A MOLECULE OF INTEREST | Imabiotech (FR) | 2015-12-30 | — | — | EP | disclosed |
| CN-105209457-A | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE DEUTSCHLAND | 2015-12-30 | — | — | CN | disclosed |
| EP-2956056-A1 | USE OF ELECTRORETINOGRAPHY (ERG) FOR THE ASSESSMENT OF PSYCHIATRIC DISORDERS | Université Laval (CA) | 2015-12-23 | — | — | EP | disclosed |
| US-9168216-B2 | Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof | VITAL HEALTH SCIENCES PTY. LTD. (AU) | 2015-10-27 | — | — | US | disclosed |
| US-9156884-B2 | Inhibitors of beta integrin-G protein alpha subunit binding interactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150283368-A1 | ON-DEMAND DRUG RELEASE USING MAGNETO- ELECTRIC NANOPARTICLES | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2015-10-08 | — | — | US | disclosed |
| EP-1893159-B1 | A CARRIER COMPRISING ONE OR MORE DI- AND/OR MONOPHOSPHATE DERIVATIVES OF ELECTRON TRANSFER AGENTS | VITAL HEALTH SCIENCES PTY LTD (AU) | 2015-09-30 | — | — | EP | disclosed |
| US-20150258097-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CATATONIA | CONOUR JAMES (US) | 2015-09-17 | — | — | US | disclosed |
| US-9133178-B2 | Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer'S disease | PROXIMAGEN LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| CN-102395558-B | Aminotetralin derivatives, the pharmaceutical composition containing described Aminotetralin derivatives and purposes in the treatment thereof | ABBVIE (US) | 2015-09-02 | — | — | CN | disclosed |
| US-20150218277-A1 | Inhibitors of the Epidermal Growth Factor Receptor- Heat Shock Protein 90 Binding Interaction | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| US-9096619-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-08-04 | — | — | US | disclosed |
| EP-2895508-A1 | INHIBITORS OF BETA INTEGRIN-G PROTEIN ALPHA SUBUNIT BINDING INTERACTIONS | The Board of Trustees of the University of Illinois (US) | 2015-07-22 | — | — | EP | disclosed |
| US-9066949-B2 | Compositions and methods for the treatment of catatonia | CONOUR JAMES (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067871-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20150158842-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-11 | — | — | US | disclosed |
| US-9051280-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9045459-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-02 | — | — | US | disclosed |
| US-9029502-B2 | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-05-12 | — | — | US | disclosed |
| US-20150111867-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-23 | — | — | US | disclosed |
| US-20150111875-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2015-04-23 | — | — | US | disclosed |
| US-8962549-B2 | Polymeric benzyl carbonate-derivatives | BAXTER INTERNATIONAL INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962018-B2 | Oral formulation of anhydrous olanzapine form I | LABORATORIOS LESVI, S.L. (ES) | 2015-02-24 | — | — | US | disclosed |
| US-20150038517-A1 | Indole Derivative Modulators of the alpha 7 nAChR | PROXIMAGEN LIMITED (GB) | 2015-02-05 | — | — | US | disclosed |
| US-20150030686-A1 | SELF-ASSEMBLED TOROIDAL-SPIRAL PARTICLES AND MANUFACTURE AND USES THEREOF | UNIV ILLINOIS (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | PROXIMAGEN LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| EP-2814810-A1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-12-24 | — | — | EP | disclosed |
| CN-104245669-A | Isoindoline derivatives, pharmaceutical compositions containing them and their use in therapy | ABBVIE DEUTSCHLAND | 2014-12-24 | — | — | CN | disclosed |
| CN-102924470-B | Novel olanzapine preparation method | JIANGSU HANSOH PHARMACEUTICAL | 2014-12-03 | — | — | CN | disclosed |
| US-8883839-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-11 | — | — | US | disclosed |
| US-8877794-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-04 | — | — | US | disclosed |
| WO-2014172344-A1 | PHARMACEUTICAL COMPOSITIONS | ALPHA TO OMEGA PHARMACEUTICAL CONSULTANTS, INC. (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140309206-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES | 2014-10-16 | — | — | US | disclosed |
| US-8853196-B2 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-07 | — | — | US | disclosed |
| US-8852645-B2 | Self-assembled toroidal-spiral particles and manufacture and uses thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-10-07 | — | — | US | disclosed |
| US-8846743-B2 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846741-B2 | N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2780328-A1 | N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbvie Deutschland GmbH & Co. KG (DE) | 2014-09-24 | — | — | EP | disclosed |
| WO-2014140310-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275087-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| WO-2014138987-A1 | USE OF ELECTRORETINOGRAPHY (ERG) FOR THE ASSESSMENT OF PSYCHIATRIC DISORDERS | UNIVERSITé LAVAL (CA) | 2014-09-18 | — | — | WO | disclosed |
| EP-2603481-B1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO KG (DE) | 2014-09-17 | — | — | EP | disclosed |
| US-20140256701-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-11 | — | — | US | disclosed |
| US-8829031-B2 | Indole derivative modulators of the alpha 7 nAChR | PROXIMAGEN LTD. (GB) | 2014-09-09 | — | — | US | disclosed |
| WO-2014128309-A1 | METHOD TO EVALUATE THE TISSUE TARGETING OF A MOLECULE OF INTEREST | IMABIOTECH (FR) | 2014-08-28 | — | — | WO | disclosed |
| CN-104011028-A | N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND | 2014-08-27 | — | — | CN | disclosed |
| US-20140228295-A1 | Inhibitors of Beta Integrin-G Protein Alpha Subunit Binding Interactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-08-14 | — | — | US | disclosed |
| US-8796283-B2 | Indole and azaindole modulators of the alpha 7 nachr | PROXIMAGEN LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| US-20140212482-A1 | MULTI-PHASE, MULTI-COMPARTMENT, CAPSULAR DELIVERY APPARATUS AND METHODS FOR USING SAME | INNERCAP TECHNOLOGIES, INC. | 2014-07-31 | — | — | US | disclosed |
| CN-103889968-A | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT GMBH & AMP | 2014-06-25 | — | — | CN | disclosed |
| EP-2739614-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co KG (DE) | 2014-06-11 | — | — | EP | disclosed |
| CN-102066356-B | Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7 | GLAXO GROUP LTD | 2014-06-11 | — | — | CN | disclosed |
| WO-2014074584-A1 | ON-DEMAND DRUG RELEASE USING MAGNETO-ELECTRIC NANOPARTICLES | KHIZROEV SAKHRAT (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20140128445-A1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | BAXTER HEALTHCARE SA (CH) | 2014-05-08 | — | — | US | disclosed |
| CN-102712622-B | Indole derivative modulators of the alpha 7 nAChR | PROXIMAGEN LTD | 2014-05-07 | — | — | CN | disclosed |
| EP-2709987-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2014-03-26 | — | — | EP | disclosed |
| WO-2014043594-A1 | INHIBITORS OF BETA INTEGRIN-G PROTEIN ALPHA SUBUNIT BINDING INTERACTIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-03-20 | — | — | WO | disclosed |
| EP-2707358-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbvie Deutschland GmbH & Co. KG (DE) | 2014-03-19 | — | — | EP | disclosed |
| CN-103145731-B | Olanzapine crystal form as well as preparation method and application thereof | JIANGSU HANSOH PHARMACEUTICAL | 2014-02-19 | — | — | CN | disclosed |
| US-8653131-B2 | Polymeric benzyl carbonate-derivatives | BAXTER HEALTHCARE S.A. (CH) | 2014-02-18 | — | — | US | disclosed |
| US-8642587-B2 | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20140031331-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20140005173-A1 | Compositions and Methods for the Treatment of Catatonia | CONOUR JAMES (US) | 2014-01-02 | — | — | US | disclosed |
| US-8617607-B2 | Sustained release formulations of psychoactive drugs | TYRX, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2488514-B1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LTD (GB) | 2013-12-25 | — | — | EP | disclosed |
| EP-1551414-B1 | Process for preparing the crystal form I of olanzapine | KRKA D D NOVO MESTO (SI) | 2013-11-27 | — | — | EP | disclosed |
| US-20130310380-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | PROXIMAGEN LIMITED (GB) | 2013-11-21 | — | — | US | disclosed |
| EP-2655401-A2 | INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR-HEAT SHOCK PROTEIN 90 BINDING INTERACTION | The Regents of the University of Michigan (US) | 2013-10-30 | — | — | EP | disclosed |
| US-8563617-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-10-22 | — | — | US | disclosed |
| CN-103328468-A | Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer's disease | PROXIMAGEN LTD | 2013-09-25 | — | — | CN | disclosed |
| EP-2632918-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | Proximagen Limited (GB) | 2013-09-04 | — | — | EP | disclosed |
| WO-2013120835-A1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-08-22 | — | — | WO | disclosed |
| US-20130210880-A1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE INC. (US) | 2013-08-15 | — | — | US | disclosed |
| CN-103237788-A | Phenalkylamine derivatives, pharmaceutical compositions containing them and their use in therapy | ABBVIE DEUTSCHLAND | 2013-08-07 | — | — | CN | disclosed |
| CN-103214414-A | Optically active diamine derivative and process for producing the same | DAIICHI SANKYO CO LTD | 2013-07-24 | — | — | CN | disclosed |
| US-20130184238-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-07-18 | — | — | US | disclosed |
| CN-103209964-A | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE DEUTSCHLAND | 2013-07-17 | — | — | CN | disclosed |
| US-8481566-B2 | 4-Fluoro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; for treatment of psychotic disorders and cognitive impairment | GLAXO GROUP LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| CN-103189337-A | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE GMBH & CO KG | 2013-07-03 | — | — | CN | disclosed |
| CN-103180299-A | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT GMBH & CO KG | 2013-06-26 | — | — | CN | disclosed |
| EP-2603493-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2013-06-19 | — | — | EP | disclosed |
| EP-2603481-A2 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2013-06-19 | — | — | EP | disclosed |
| EP-2603487-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2013-06-19 | — | — | EP | disclosed |
| CN-102234285-B | Preparation method of olanzapine | JIANGSU HANSOH PHARMACEUTICAL | 2013-06-12 | — | — | CN | disclosed |
| CN-103145731-A | Olanzapine crystal form as well as preparation method and application thereof | JIANGSU HANSOH PHARMACEUTICAL | 2013-06-12 | — | — | CN | disclosed |
| CN-102924472-B | Preparation method for olanzapine | JIANGSU HANSOH PHARMACEUTICAL | 2013-06-05 | — | — | CN | disclosed |
| US-20130137646-A1 | METHODS OF TREATMENT, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
| US-20130136791-A1 | MULTI-PHASE, MULT-COMPARTMENT CAPSULAR DELIVERY APPARATUS AND METHODS FOR USING SAME | MILLER FRED H (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2013072520-A1 | N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-05-23 | — | — | WO | disclosed |
| US-20130131132-A1 | N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-1996188-B1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2013-05-15 | — | — | EP | disclosed |
| EP-2004182-B1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2013-05-08 | — | — | EP | disclosed |
| EP-2344483-B1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-05-01 | — | — | EP | disclosed |
| CN-103058990-A | Benzimidazoles which have activity at m1 receptor and uses thereof in medicine | GLAXO GROUP LTD | 2013-04-24 | — | — | CN | disclosed |
| US-8426443-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2013-04-23 | — | — | US | disclosed |
| CN-101263110-B | Optically active diamine derivative and process for producing the same | DAIICHI SANKYO CO LTD | 2013-04-03 | — | — | CN | disclosed |
| US-20130071484-A1 | Self-Assembled Toroidal-Spiral Particles and Manufacture and Uses Thereof | THE BOARD OF TRUSTEES OF THE UNIVERISTY OF ILLINOIS (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072433-A1 | INHIBITORS OF BETA INTEGRIN-G PROTEIN ALPHA SUBUNIT BINDING INTERACTIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2419420-B1 | INDOLE DERIVATIVE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LTD (GB) | 2013-03-13 | — | — | EP | disclosed |
| CN-102942573-A | Preparation method of olanzapine | JIANGSU HANSOH PHARMACEUTICAL | 2013-02-27 | — | — | CN | disclosed |
| US-8377941-B2 | Indoles as modulators of nicotinic acetylcholine receptor subtype alpha-7 | PROXIMAGEN LIMITED (GB) | 2013-02-19 | — | — | US | disclosed |
| WO-2013020930-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2013-02-14 | — | — | WO | disclosed |
| CN-102924472-A | Preparation method for olanzapine | JIANGSU HANSOH PHARMACEUTICAL | 2013-02-13 | — | — | CN | disclosed |
| CN-102924470-A | Olanzapine preparation method | JIANGSU HANSOH PHARMACEUTICAL | 2013-02-13 | — | — | CN | disclosed |
| US-20130035323-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2013-02-07 | — | — | US | disclosed |
| US-8361497-B2 | Multi-phase, multi-compartment, capsular delivery apparatus and methods for using the same | INNERCAP TECHNOLOGIES, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2548581-A2 | A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof | Vital Health Sciences Pty Ltd. (AU) | 2013-01-23 | — | — | EP | disclosed |
| EP-2547359-A2 | INHIBITORS OF BETA INTEGRIN-G PROTEIN ALPHA SUBUNIT BINDING INTERACTIONS | The Board of Trustees of the University of Illinois (US) | 2013-01-23 | — | — | EP | disclosed |
| US-8344000-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2013-01-01 | — | — | US | disclosed |
| US-20120316153-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316196-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2012-12-13 | — | — | US | disclosed |
| US-20120316202-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED | 2012-12-13 | — | — | US | disclosed |
| US-20120309789-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED | 2012-12-06 | — | — | US | disclosed |
| WO-2012163990-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS TREATED WITH NEUROLEPTIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | WO | disclosed |
| US-20120295881-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-22 | — | — | US | disclosed |
| WO-2012153347-A2 | ORAL PHARMACEUTICAL COMPOSITION OF OLANZAPINE FORM 1 | ZENTIVA K.S. (CZ) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012152915-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-15 | — | — | WO | disclosed |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (UK) | 2012-11-08 | — | — | US | disclosed |
| US-8299257-B2 | Compounds which have activity at M1receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8288412-B2 | Psychological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8283364-B2 | Psyvhological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| US-8283365-B2 | Indole modulators of the alpha 7 nicotinic acetylcholine receptor | PROXIMAGEN LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| CN-102712622-A | Indole derivative modulators of the alpha 7 nAChR | PROXIMAGEN LTD | 2012-10-03 | — | — | CN | disclosed |
| US-8278328-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| WO-2012129232-A1 | COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC OR NEUROLOGICAL DISORDERS | CONOUR JAMES (US) | 2012-09-27 | — | — | WO | disclosed |
| EP-1996189-B1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2012-09-26 | — | — | EP | disclosed |
| WO-2012110222-A1 | RAPIDLY DISINTEGRATING ORAL FILM FORMULATION FOR OLANZAPIN | LABTEC GMBH (DE) | 2012-08-23 | — | — | WO | disclosed |
| EP-2488514-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | Proximagen Limited (GB) | 2012-08-22 | — | — | EP | disclosed |
| EP-2486913-A1 | Rapidly disintegrating oral film formulation for Olanzapin | Labtec GmbH (DE) | 2012-08-15 | — | — | EP | disclosed |
| EP-1960389-B1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| EP-2279183-B1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | PROXIMAGEN LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| EP-2279184-B1 | INDOLE MODULATORS OF THE ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR | PROXIMAGEN LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| US-20120190622-A1 | INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR-HEAT SHOCK PROTEIN 90 BINDING INTERACTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2012087943-A2 | INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR-HEAT SHOCK PROTEIN 90 BINDING INTERACTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120136009-A1 | INDOLE DERIVATIVE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LTD (GB) | 2012-05-31 | — | — | US | disclosed |
| WO-2012055942-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | PROXIMAGEN LIMITED (GB) | 2012-05-03 | — | — | WO | disclosed |
| US-20120093923-A1 | Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses, Or Conditions | INNERCAP TECHNOLOGIES, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120088790-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-04-12 | — | — | US | disclosed |
| CN-101321736-B | To M1Compounds with receptor activity and their use in medicine | GLAXO GROUP LTD | 2012-04-04 | — | — | CN | disclosed |
| US-20120077796-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120058185-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF OLANZAPINE AND PROCESS FOR THEIR PREPARATION | ALKEM LABORATORIES LIMITED (IN) | 2012-03-08 | — | — | US | disclosed |
| US-8129522-B2 | Method for preparing a mixed solvate of olanzapine | INKE, S.A. (ES) | 2012-03-06 | — | — | US | disclosed |
| EP-2419420-A1 | INDOLE DERIVATIVE MODULATORS OF THE ALPHA 7 NACHR | Glaxo Group Limited (GB) | 2012-02-22 | — | — | EP | disclosed |
| WO-2012020130-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012020134-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012020131-A2 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012020133-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
| US-20120041027-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
| US-20120040948-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120004273-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | AHMAD NADIA MAMOONA (GB) | 2012-01-05 | — | — | US | disclosed |
| US-8088814-B2 | Administering a cyclooxygenase inhibitor; treating schizophrenia, delusional disorders, affective disorders, autism or tic disorders | MUELLER NORBERT (DE) | 2012-01-03 | — | — | US | disclosed |
| EP-2396296-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2011-12-21 | — | — | EP | disclosed |
| EP-2396323-A1 | Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1 | Abbott GmbH & Co. KG (DE) | 2011-12-21 | — | — | EP | disclosed |
| CN-102234285-A | Preparation method of olanzapine | JIANGSU HANSOH PHARMACEUTICAL | 2011-11-09 | — | — | CN | disclosed |
| US-20110268699-A1 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES | BIOVISTA, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2375900-A1 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES | Biovista, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2011116026-A2 | INHIBITORS OF BETA INTEGRIN-G PROTEIN ALPHA SUBUNIT BINDING INTERACTIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110213193-A1 | Magnetic Nanodelivery of Therapeutic Agents Across the Blood Brain Barrier | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110207777-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | TELECOM IP LIMITED | 2011-08-25 | — | — | US | disclosed |
| US-20110178131-A1 | Compounds Which Have Activity At M1 Receptor And Their Uses In Medicine | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| EP-1730153-B1 | ISOPROPANOL WATER SOLVATE OF OLANZAPINE | KRKA TOVARNA ZDRAVIL D D NOVO MESTO (SI) | 2011-07-20 | — | — | EP | disclosed |
| EP-2344483-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | Glaxo Group Limited (GB) | 2011-07-20 | — | — | EP | disclosed |
| EP-2343058-A2 | A pharmaceutical formulation containing olanzapine | Actavis Group PTC ehf. (IS) | 2011-07-13 | — | — | EP | disclosed |
| WO-2011080401-A1 | RECEPTOR TYROSINE KINASE-BINDING COMPOSITIONS | LICENTIA LTD (FI) | 2011-07-07 | — | — | WO | disclosed |
| EP-2328619-A2 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | Baxter International Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20110130423-A1 | Compounds Which Have Activity At M1 Receptor And Their Uses In Medicine | GLAXO GROUP LIMITED, | 2011-06-02 | — | — | US | disclosed |
| US-20110130390-A1 | Use of COX-2 Inhibitors for the Treatment of Schizophrenia, Delusional Disorders, Affective Disorders, Autism or Tic Disorders | MUELLER NORBERT | 2011-06-02 | — | — | US | disclosed |
| WO-2011062936-A2 | SELF-ASSEMBLED TOROIDAL-SPIRAL PARTICLES AND MANUFACTURE AND USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-05-26 | — | — | WO | disclosed |
| CN-102066356-A | Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7 | GLAXO GROUP LTD | 2011-05-18 | — | — | CN | disclosed |
| CN-102066357-A | Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71 | GLAXO GROUP LTD | 2011-05-18 | — | — | CN | disclosed |
| EP-1963335-B1 | PROCESS FOR THE PREPARATION OF OLANZAPINE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKOEDOE RESZVENYTARSASAG (HU) | 2011-05-04 | — | — | EP | disclosed |
| WO-2011045353-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (GB) | 2011-04-21 | — | — | WO | disclosed |
| EP-1965773-B1 | ORAL FORMULATION OF ANHYDROUS OLANZAPINE FORM I | LESVI LABORATORIOS SL (ES) | 2011-04-06 | — | — | EP | disclosed |
| US-7906642-B2 | Isopropanol water solvate of olanzapine | KRKA, TOVARNA ZDRAVIL, D.D. (SI) | 2011-03-15 | — | — | US | disclosed |
| EP-2292624-A1 | Process for the purification of olanzapine | LEK Pharmaceuticals d.d. (SI) | 2011-03-09 | — | — | EP | disclosed |
| EP-2289497-A1 | Once-daily administration of central nervous system drugs | Circ Pharma Research and Development Limited (IE) | 2011-03-02 | — | — | EP | disclosed |
| US-20110034515-A1 | INDOLE MODULATORS OF THE ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR | GLAXOSMITHKLINE SERVICES UNLIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXOSMITHKLINE SERVICES UNLIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| WO-2011012622-A1 | BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-02-03 | — | — | WO | disclosed |
| EP-2279183-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | Glaxo Group Limited (GB) | 2011-02-02 | — | — | EP | disclosed |
| EP-2279184-A1 | INDOLE MODULATORS OF THE ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR | Glaxo Group Limited (GB) | 2011-02-02 | — | — | EP | disclosed |
| US-20110021507-A1 | INHIBITING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN | THERACOS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2011011238-A1 | INHIBITING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN | THERACOS, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011009831-A1 | PROCESS FOR THE PURIFICATION OF OLANZAPINE | LEK PHARMACEUTICALS D.D. (SI) | 2011-01-27 | — | — | WO | disclosed |
| US-20110009440-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | MARSHALL HOWARD ROBERT | 2011-01-13 | — | — | US | disclosed |
| US-20110009378-A1 | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy | ABBOTT GMBH & CO. KG (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-1292573-B1 | SUBSTITUTED THIOACETAMIDES | CEPHALON INC (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1943230-B1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2010-12-22 | — | — | EP | disclosed |
| US-20100317704-A1 | SPIRO-CONDENSED IMIDAZOLONE DERIVATIVES INHIBITING THE GLYCINE TRANSPORTER | Glaxo Group Limited a corporation | 2010-12-16 | — | — | US | disclosed |
| WO-2010134097-A2 | STABLE PHARMACEUTICAL COMPOSITIONS OF OLANZAPINE AND PROCESS FOR THEIR PREPARATION | ALKEM LABORATORIES LTD. (IN) | 2010-11-25 | — | — | WO | disclosed |
| EP-1968983-B1 | METHOD FOR PREPARING A MIXED SOLVATE OF OLANZAPINE | INKE SA (ES) | 2010-11-24 | — | — | EP | disclosed |
| EP-2247284-A2 | PROCESS TO MINIMIZE POLYMORPHISM | R.P. Scherer Technologies, LLC (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20100280071-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| EP-2246046-A1 | Orally disintegrating olanzapine tablet | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2010-11-03 | — | — | EP | disclosed |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | ABBVIE INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100272800-A1 | ORALLY DISINTEGRATING OLANZAPINE TABLET | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2010-10-28 | — | — | US | disclosed |
| WO-2010119078-A1 | INDOLE DERIVATIVE MODULATORS OF THE ALPHA 7 NACHR | GLAXO GROUP LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| US-20100266711-A1 | THIENOBENZODIAZEPINE MODULATORS OF D1 RECEPTOR, D2 RECEPTOR, AND/OR 5-HT2 RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100266711-A1 | THIENOBENZODIAZEPINE MODULATORS OF D1 RECEPTOR, D2 RECEPTOR, AND/OR 5-HT2 RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7807828-B2 | Olanzapine analogs and methods of use thereof | HYPNION, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100233254-A1 | MULTI-PHASE, MULTI-COMPARTMENT, CAPSULAR DELIVERY APPARATUS AND METHODS FOR USING THE SAME | INNERCAP TECHNOLOGIES, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100221321-A1 | Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions | INNERCAP TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| EP-1928428-B1 | A PHARMACEUTICAL FORMULATION CONTAINING OLANZAPINE | ACTAVIS GROUP PTC EHF (IS) | 2010-09-01 | — | — | EP | disclosed |
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100210687-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| WO-2010092181-A1 | HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | ABBOTT GMBH & CO. KG (DE) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010092180-A1 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT GMBH & CO. KG (DE) | 2010-08-19 | — | — | WO | disclosed |
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | Glaxo Group Limited a corporation | 2010-08-12 | — | — | US | disclosed |
| US-20100190825-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | COOPER DAVID GWYN | 2010-07-29 | — | — | US | disclosed |
| US-7759484-B2 | Mixed solvate of olanzapine, method for preparing it and method for preparing form I of olanzapine therefrom | INKE, S.A. (ES) | 2010-07-20 | — | — | US | disclosed |
| US-7745429-B2 | olanzapine is crystallized using the non-harmful solvent mixture of isopropanol | KRKA, D.D. NOVO MESTO (SI) | 2010-06-29 | — | — | US | disclosed |
| EP-2197852-A1 | SPIRO-CONDENSED IMIDAZOLONE DERIVATIVES INHIBITING THE GLYCINE TRANSPORTER | Glaxo Group Limited (GB) | 2010-06-23 | — | — | EP | disclosed |
| EP-2197441-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | Glaxo Group Limited (GB) | 2010-06-23 | — | — | EP | disclosed |
| WO-2010068867-A1 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES | BIOVISTA, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| EP-2194982-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | Glaxo Group Limited (GB) | 2010-06-16 | — | — | EP | disclosed |
| EP-2194983-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | Glaxo Group Limited (GB) | 2010-06-16 | — | — | EP | disclosed |
| US-20100137428-A1 | OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS | GLAXO GROUP LIMITED | 2010-06-03 | — | — | US | disclosed |
| EP-1833811-B1 | OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS | GLAXO GROUP LTD (GB) | 2010-06-02 | — | — | EP | disclosed |
| US-20100130478-A1 | SUSTAINED RELEASE FORMULATIONS OF PSYCHOACTIVE DRUGS | TYRX PHARMA, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| EP-2186803-A2 | Substituted thioacetamides | CEPHALON, INC. (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20100113545-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | COULTON STEVEN | 2010-05-06 | — | — | US | disclosed |
| US-20100105713-A1 | GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| EP-2043612-B1 | A STABLE OLANZAPINE FORMULATION WITH ANTIOXIDANTS | BILIM ILAC SANAYII VE TICARET (TR) | 2010-04-28 | — | — | EP | disclosed |
| WO-2010037723-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010025322-A2 | MAGNETIC NANODELIVERY OF THERAPEUTIC AGENTS ACROSS THE BLOOD BRAIN BARRIER | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2010-03-04 | — | — | WO | disclosed |
| US-7670612-B2 | Supplying active materials in various phases in single dosage multicompartment capsule | INNERCAP TECHNOLOGIES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20100048656-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | AHMAD NADIA MAMOONA | 2010-02-25 | — | — | US | disclosed |
| WO-2010022320-A2 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | BAXTER INTERNATIONAL INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048483-A1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | BAXTER HEALTHCARE S.A. (CH) | 2010-02-25 | — | — | US | disclosed |
| WO-2010018214-A1 | PYRROLIDINONE DERIVATIVES USEFUL FOR THE TREATEMENT OF PSYCHOTIC AND NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018213-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-02-18 | — | — | WO | disclosed |
| US-20100029700-A1 | 1-(2-ARYL-2-OXOETHYL)-3-PHENYL-1, 4-DIAZASPIRO [4.5]DEC-3-EN-2-ONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| WO-2010010133-A1 | 2-THIA-1,3-DIAZASPIROCYCLIC-SUBSTITUTED PHENYLACETAMIDES AS GLT1 MEDIATORS FOR NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2010-01-28 | — | — | WO | disclosed |
| US-20100016399-A1 | GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | AHMAD NADIA MAMOONA | 2010-01-21 | — | — | US | disclosed |
| US-20100016374-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| WO-2010006249-A1 | SUSTAINED RELEASE FORMULATIONS OF PSYCHOACTIVE DRUGS | TYRX PHARMA, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20090326027-A1 | N-Phenyl-2-0X0-1,4-Diazaspiro [4.5] Dec-3-EN-1-YL Acetamide Derivatives And Their Use As Glycine Transporter Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325993-A1 | GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | AHMAD NADIA MAMOONA | 2009-12-31 | — | — | US | disclosed |
| US-20090318683-A1 | METHOD FOR PREPARING A MIXED SOLVATE OF OLANZAPINE | INKE, S.A. (ES) | 2009-12-24 | — | — | US | disclosed |
| EP-1627639-B1 | Use of COX-2 inhibitors for the treatment of affective disorders | MUELLER NORBERT (DE) | 2009-12-23 | — | — | EP | disclosed |
| EP-2121623-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Glaxo Group Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| EP-2121606-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Glaxo Group Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| EP-2121624-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Glaxo Group Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| EP-2121625-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Glaxo Group Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| EP-2121622-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Glaxo Group Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| EP-2121690-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Glaxo Group Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090281078-A1 | COMBINATION OF SABCOMELINE WITH A NEUROLEPTIC AGENT TO TREAT PSYCHOTIC DISORDERS | MINSTER RESEARCH LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| EP-1915379-B1 | OLANZAPINE ANALOGS AND METHODS OF USE THEREOF | HYPNION INC (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090270510-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| WO-2009127678-A1 | INDOLES AS MODULATORS OF NICOTINIC ACETYLCHOLIN RECEPTOR SUBTYPE ALPHA-71 | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009127679-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | disclosed |
| EP-2108018-A2 | 8-OXA-1,4-DIAZASPIRO [4,5] DEC-3-EN-1-YL AND 1,4,8-TRIAZASPIRO [4,5] DEC-3-EN-1-YL ACETAMIDES AS GLYTI TRANSPORTER INHIBITORS IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Glaxo Group Limited (GB) | 2009-10-14 | — | — | EP | disclosed |
| US-20090253700-A1 | N-'4-4(4-MORPHOLINYL) PHENYL!- '(4-PIPERIDINYL) METHYL! CARBOXAMIDE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| EP-2041082-B1 | PYRROLIDINE DERIVATIVES HAVING ACTIVITY AT THE GLYT1 TRANSPORTER | GLAXO GROUP LTD (GB) | 2009-09-30 | — | — | EP | disclosed |
| US-20090226522-A1 | PROCESS TO MINIMIZE POLYMORPHISM | R.P. SCHERER TECHNOLOGIES, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090221577-A1 | COMPOUNDS HAVING MORPHOLINYL AND PIPERIDINYL GROUPS FOR USE AS GLYT1 INHIBITORS | GLAXO GROUP LIMITED | 2009-09-03 | — | — | US | disclosed |
| US-20090221560-A1 | Pharmaceutical Formulation | ACTAVIS GROUP PTC EHF | 2009-09-03 | — | — | US | disclosed |
| WO-2009108775-A2 | PROCESS TO MINIMIZE POLYMORPHISM | R.P. SCHERER TECHNOLOGIES, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| CN-101506156-A | Pyrrolidine derivatives having activity at the GlyT1 transporter | GLAXO GROUP LTD (GB) | 2009-08-12 | — | — | CN | disclosed |
| US-20090163475-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-1438288-B1 | SUBSTITUTED THIOACETAMIDES | CEPHALON INC (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-2043612-A1 | A STABLE OLANZAPINE FORMULATION WITH ANTIOXIDANTS | Bilim Ilac Sanayii Ve Ticaret A.S. (TR) | 2009-04-08 | — | — | EP | disclosed |
| EP-2041082-A1 | PYRROLIDINE DERIVATIVES HAVING ACTIVITY AT THE GLYT1 TRANSPORTER | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2009037296-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037294-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037293-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009034062-A1 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009034061-A1 | SPIRO-CONDENSED IMIDAZOLONE DERIVATIVES INHIBITING THE GLYCINE TRANSPORTER | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| EP-2027098-A1 | 1-(2-ARYL-2-OXOETHYL)-3-PHENYL-1, 4-DIAZASPIRO (4.5)DEC-3-EN-2-ONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS | Glaxo Group Limited (GB) | 2009-02-25 | — | — | EP | disclosed |
| US-20090036354-A1 | CARRIER COMPRISING ONE OR MORE DI AND/OR MONO-(ELECTRON TRANSFER AGENT) PHOSPHATE DERIVATIVES OR COMPLEXES THEREOF | ISP INVESTMENTS LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035332-A1 | PHARMACEUTICAL FORMULATION | ACTAVIS GROUP PTC EHF | 2009-02-05 | — | — | US | disclosed |
| EP-1838663-B1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LTD (GB) | 2009-01-21 | — | — | EP | disclosed |
| EP-2013173-A2 | PYRIDINE-, ISOXAZOLE, THIOPHENECARBOXAMIDE COMPOUNDS HAVING ACTIVITY AT THE GLYCINE TRANSPORTER GLYT1 AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20090005366-A1 | DEUTERIUM-ENRICHED OLANZAPINE | PROTIA, LLC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080317849-A1 | Method for Improving the Medical Treatment of Pain | OSTEOLOGIX A/S (DK) | 2008-12-25 | — | — | US | disclosed |
| EP-2004182-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | EP | disclosed |
| EP-2004612-A1 | N-PHENYL-2-0X0-1,4-DIAZASPIR0 [4.5]DEC-3-EN-1-YL ACETAMIDE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008157562-A2 | DEUTERIUM-ENRICHED OLANZAPINE | PROTIA LLC (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080311203-A1 | Oral Formulation of Anhydrous Olanzapine Form I | LABORATORIES LESVI, S. I. (ES) | 2008-12-18 | — | — | US | disclosed |
| EP-2001831-A2 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306043-A1 | Sabcomeline Alone or Combined with a Mood Stabilising or Antimanic Agent to Treat Bipolar Disorders | MINSTER RESEARCH LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| CN-101321736-A | To M1Compounds with receptor activity and their use in medicine | GLAXO GROUP LTD (GB) | 2008-12-10 | — | — | CN | disclosed |
| EP-1996189-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-12-03 | — | — | EP | disclosed |
| EP-1996188-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-12-03 | — | — | EP | disclosed |
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| EP-1994010-A1 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2008-11-26 | — | — | EP | disclosed |
| CN-101311179-A | Improved process for preparing thieno-benzodiazepine compounds | UNIV EAST CHINA SCIENCE & TECH (CN) | 2008-11-26 | — | — | CN | disclosed |
| CN-101311179-A | Improved process for preparing thieno-benzodiazepine compounds | UNIV EAST CHINA SCIENCE & TECH (CN) | 2008-11-26 | — | — | CN | disclosed |
| CN-101311179-A | Improved process for preparing thieno-benzodiazepine compounds | UNIV EAST CHINA SCIENCE & TECH (CN) | 2008-11-26 | — | — | CN | disclosed |
| WO-2007147839-A9 | GLYCINE TRANSPORTER INHIBITING COMPOUNDS AND USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2008-11-13 | — | — | WO | disclosed |
| US-20080280884-A1 | Mixed Solvate of Olanzapine, Method for Preparing It and Method for Preparing Form I of Olanzapine Therefrom | INKE, S.A. (ES) | 2008-11-13 | — | — | US | disclosed |
| US-20080255195-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| WO-2008119713-A1 | 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119711-A1 | SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119716-A1 | 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119715-A1 | 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119712-A1 | BENZOIMIDAZOLE DERIVATIVES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119714-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119717-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119718-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119721-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119719-A1 | 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119720-A1 | 1-(1-CYCLOBUTYL-4-PIPERIDINYL)-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| EP-1968983-A1 | METHOD FOR PREPARING A MIXED SOLVATE OF OLANZAPINE | INKE, S.A. (ES) | 2008-09-17 | — | — | EP | disclosed |
| US-7425627-B2 | Methods of synthesizing olanzapine | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-09-16 | — | — | US | disclosed |
| US-20080221185-A1 | Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| EP-1965773-A1 | ORAL FORMULATION OF ANHYDROUS OLANZAPINE FORM I | Laboratorios Lesvi, S. L. (ES) | 2008-09-10 | — | — | EP | disclosed |
| EP-1959936-A2 | ONCE-DAILY ADMINISTRATION OF CENTRAL NERVOUS SYSTEM DRUGS | Circ Pharma Research and Development Limited (IE) | 2008-08-27 | — | — | EP | disclosed |
| EP-1960389-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008092878-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092879-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092877-A2 | 8-OXA-1, 4-DIAZASPIRO [4,5] DEC-3-EN-1-YL AND 1,4, 8-TRIAZASPIRO [4,5] DEC- 3-EN-1-YL ACETAMIDES AS GLYTI TRANSPORTER INHIBITORS IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092876-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092873-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092872-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092874-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| EP-1951205-A2 | STABLE COMPOSITION FOR A PHARMACEUTICAL FORMULATION CONTAINING OLANZAPINE | Actavis Group PTC EHF (IS) | 2008-08-06 | — | — | EP | disclosed |
| EP-1943230-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| US-20080161557-A1 | Synthesis of 2-Methyl-4-(4-Methyl-1-Piperazinly)-10H-Thieno(2,3-B) (1,5) Benzodiazepine and Salts Thereof | LEK PHARMACEUTICALS D.D. (SL) | 2008-07-03 | — | — | US | disclosed |
| EP-1937670-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT M1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-07-02 | — | — | EP | disclosed |
| EP-1928428-A2 | A PHARMACEUTICAL FORMULATION CONTAINING OLANZAPINE | Actavis Group PTC EHF (IS) | 2008-06-11 | — | — | EP | disclosed |
| EP-1611139-B1 | METHODS OF PREPARING OLANZAPINE | TEVA PHARMA (IL) | 2008-06-04 | — | — | EP | disclosed |
| CN-101184735-A | Crystalline form of benzazepinium maleate derivative | GLAXO GROUP LTD (GB) | 2008-05-21 | — | — | CN | disclosed |
| EP-1915379-A1 | OLANZAPINE ANALOGS AND METHODS OF USE THEREOF | Hypnion, Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1910311-A2 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-04-16 | — | — | EP | disclosed |
| US-20080081804-A1 | Combination of Sabcomeline with a Neuroleptic Agent to Treat Psychotic Disorders | MINSTER RESEARCH LIMITED (GB) | 2008-04-03 | — | — | US | disclosed |
| US-20080070973-A1 | Compounds having activity at the GlyT1 transporter | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | US | disclosed |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| EP-1893159-A1 | A CARRIER COMPRISING ONE OR MORE DI AND/OR MONO-(ELECTRON TRANSFER AGENT) PHOSPHATE DERIVATIVES OR COMPLEXES THEREOF | Vital Health Sciences Pty Ltd. (AU) | 2008-03-05 | — | — | EP | disclosed |
| CN-101133018-A | Glycine transport inhibitors | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | CN | disclosed |
| EP-1890700-A2 | METHODS AND COMPOSITIONS FOR MANAGING PSYCHOTIC DISORDERS | Orexigen Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1885699-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2008-02-13 | — | — | EP | disclosed |
| EP-1884243-A1 | Use of an antipsychotic drug for the treatment of ALS-associated cachexia | Charité - Universitätsmedizin Berlin (DE) | 2008-02-06 | — | — | EP | disclosed |
| US-20080027228-A1 | Substituted thioacetamides | CEPHALON, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-RE40033-E1 | Process for preparing 2-methyl-thieno-benzodiazepine | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| US-20080009481-A1 | Process For Making Form I Of Olanzapine | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2008-01-10 | — | — | US | disclosed |
| WO-2008004033-A1 | A STABLE OLANZAPINE FORMULATION WITH ANTIOXIDANTS | BILIM ILAC SANAYII VE TICARET A.S. (TR) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007147836-A1 | GLYCINE TRANSPORTER INHIBITING COMPOUNDS AND USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147831-A1 | PYRROLIDINE DERIVATIVES HAVING ACTIVITY AT THE GLYT1 TRANSPORTER | GLAXO GROUP LIMITED (GB) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147834-A1 | GLYCINE TRANSPORTER INHIBITING COMPOUNDS AND USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147839-A1 | GLYCINE TRANSPORTER INHIBITING COMPOUNDS AND USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007144901-A1 | PROCESS FOR STABILIZATION OF OLANZAPINE POLYMORPHIC FORM I | JUBILANT ORGANOSYS LIMITED (IN) | 2007-12-21 | — | — | WO | disclosed |
| EP-1773841-B1 | MIXED SOLVATE OF OLANZAPINE, METHOD FOR PREPARING IT AND METHOD FOR PREPARING FORM I OF OLANZAPINE THEREFROM | INKE SA (ES) | 2007-12-05 | — | — | EP | disclosed |
| CN-101084222-A | Synthesis of 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno[2, 3-b][1,5]benzodiazepine and salts thereof | LEK PHARMACEUTICALS (SI) | 2007-12-05 | — | — | CN | disclosed |
| WO-2007137224-A2 | METHOD OF TREATMENT | VANDA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070275948-A1 | 7-[4-(4-Chlorobenzyloxy)Benzenesulfonyl]-8-Methoxy-3-Methyl-2,3,4,5-Tetrahydro-1h-3-Benzazepinium Maleate Or Tosylate As antipyschotics | GLAXO GROUP LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| EP-1858869-A1 | ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| EP-1858868-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007132293-A2 | ONCE-DAILY ADMINISTRATION OF CENTRAL NERVOUS SYSTEM DRUGS | CIRC PHARMA RESEARCH AND DEVELOPMENT LIMITED (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-1856077-A1 | PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-11-21 | — | — | EP | disclosed |
| WO-2007128442-A1 | USE OF AN ANTIPSYCHOTIC DRUG FOR THE TREATMENT OF ALS-ASSOCIATED CACHEXIA | Charité-Universitätsmedizin Berlin (DE) | 2007-11-15 | — | — | WO | disclosed |
| EP-1846375-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007116061-A1 | 1-(2-ARYL-2-OXOETHYL)-3-PHENYL-1, 4-DIAZASPIRO [4.5]DEC-3-EN-2-ONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007113309-A2 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| EP-1841727-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-10-10 | — | — | EP | disclosed |
| EP-1838663-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-10-03 | — | — | EP | disclosed |
| EP-1838310-A1 | COMBINATION OF SABCOMELINE WITH A NEUROLEPTIC AGENT TO TREAT PSYCHOTIC DISORDERS | Minster Research Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007107565-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107566-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107567-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| US-20070225276-A1 | 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | US | disclosed |
| EP-1835914-A1 | SABCOMELINE ALONE OR COMBINED WITH A MOOD STABILISING OR ANTIMANIC AGENT TO TREAT BIPOLAR DISORDERS | Minster Research Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| WO-2007104776-A1 | N-PHENYL-2-0X0-1,4-DIAZASPIR0 [4.5] DEC-3-EN-1-YL ACETAMIDE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104775-A1 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | WO | disclosed |
| EP-1833811-A1 | OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-09-19 | — | — | EP | disclosed |
| US-7268132-B2 | Thio substituted with a hetero multiring group; sleepiness, promotion of wakefulness, Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, attention deficit hyperactivity disorder | CEPHALON, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| WO-2007093587-A1 | USE OF R-(-)-2,4-DIAMINO-5-(2, 3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191348-A1 | Isopropanol water solvate of olanzapine | KRKA, TOVARNA ZDRAVIL, D.D. (SI) | 2007-08-16 | — | — | US | disclosed |
| EP-1423124-B1 | LYOPHILIZED FORMULATION COMPRISING OLANZAPINE | LILLY CO ELI (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2007080159-A2 | PYRIDINE-, ISOXAZOLE, THIOPHENECARBOXAMIDE COMPOUNDS HAVING ACTIVITY AT THE GLYCINE TRANSPORTER GLYT1 AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007077134-A1 | METHOD FOR PREPARING A MIXED SOLVATE OF 0LANZAPINE | INKE, S.A. (ES) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007074110-A1 | ORAL FORMULATION OF ANHYDROUS OLANZAPINE FORM I | LABORATORIOS LESVI, S.L. (ES) | 2007-07-05 | — | — | WO | disclosed |
| US-20070142411-A1 | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| WO-2007052167-A2 | STABLE COMPOSITION FOR A PHARMACEUTICAL FORMULATION CONTAINING OLANZAPINE | ACTAVIS GROUP PTC EHF (IS) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007052164-A2 | A PHARMACEUTICAL FORMULATION CONTAINING OLANZAPINE | ACTAVIS GROUP PTC EHF (IS) | 2007-05-10 | — | — | WO | disclosed |
| US-20070104788-A1 | Once-daily administration of central nervous system drugs | CIRC PHARMA RESEARCH AND DEVELOPMENT LIMITED (IE) | 2007-05-10 | — | — | US | disclosed |
| EP-1781666-A1 | IMPROVED PROCESS FOR MAKING FORM I OF OLANZAPINE. | Shasun Chemicals and Drugs Limited (IN) | 2007-05-09 | — | — | EP | disclosed |
| US-20070093473-A1 | 7-Heteroarylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents | GLAXO GROUP LIMITED | 2007-04-26 | — | — | US | disclosed |
| EP-1773841-A1 | MIXED SOLVATE OF OLANZAPINE, METHOD FOR PREPARING IT AND METHOD FOR PREPARING FORM I OF OLANZAPINE THEREFROM | INKE, S.A. (ES) | 2007-04-18 | — | — | EP | disclosed |
| US-RE39575-E1 | Substituted thioacetamides | CEPHALON, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2007036715-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036711-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036718-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| EP-1758652-A2 | IMPROVING PAIN TREATMENT WITH STRONTIUM COMBINATIONS | Osteologix A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| US-20070043021-A1 | derivatives of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for modulating sleep disorder; side effect reduction | HYPNION, INC. | 2007-02-22 | — | — | US | disclosed |
| WO-2007022068-A1 | OLANZAPINE ANALOGS AND METHODS OF USE THEREOF | HYPNION, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007014762-A2 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| EP-1749010-A2 | SYNTHESIS OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO 2, 3-B 1,5 BENZODIAZEPINE AND SALTS THEREOF | LEK Pharmaceuticals D.D. (SI) | 2007-02-07 | — | — | EP | disclosed |
| CN-1906170-A | 7- [ 4- (4-chlorobenzyloxy) benzenesulfonyl ] -8-methoxy-3-methyl-2, 3,4, 5-tetrahydro-1H-3-benzazepine * onium maleate or tosylate salt for use as antipsychotic agent | GLAXO GROUP LTD (GB) | 2007-01-31 | — | — | CN | disclosed |
| CN-1906201-A | Method for synthesizing olanzapine | TEVA PHARMA (IL) | 2007-01-31 | — | — | CN | disclosed |
| WO-2006133506-A1 | A CARRIER COMPRISING ONE OR MORE DI AND/OR MONO-(ELECTRON TRANSFER AGENT) PHOSPHATE DERIVATIVES OR COMPLEXES THEREOF | VITAL HEALTH SCIENCES PTY LTD (AU) | 2006-12-21 | — | — | WO | disclosed |
| EP-1730153-A1 | ISOPROPANOL WATER SOLVATE OF OLANZAPINE | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2006-12-13 | — | — | EP | disclosed |
| US-20060276412-A1 | METHODS AND COMPOSITIONS FOR MANAGING PSYCHOTIC DISORDERS | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2006-12-07 | — | — | US | disclosed |
| WO-2006130522-A2 | METHODS AND COMPOSITIONS FOR MANAGING PSYCHOTIC DISORDERS | OREXIGEN THERAPEUTICS, INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006125622-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2006-11-30 | — | — | WO | disclosed |
| US-20060223794-A1 | Novel olanzapine forms and related methods of treatment | TRANSFORM PHAMACEUTICALS, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094843-A1 | PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094840-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| EP-1687005-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | disclosed |
| EP-1687001-A2 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | disclosed |
| EP-1687279-A1 | 7- [4-(4-CHLOROBENZYLOXY) BENZENESULFONYL]-8-METHOXY-3-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINIUM MALEATE OR TOSYLATE AS ANTIPSYCHOTICS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-20060167074-A1 | Methods and compositions for the treatment of psychiatric disorders | MULLER NORBERT | 2006-07-27 | — | — | US | disclosed |
| WO-2006076124-A2 | STABLE, NON-CRYSTALLINE FORMULATION COMPRISING OLANZAPINE | NEKTAR THERAPEUTICS (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006067430-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067437-A1 | OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067494-A1 | SABCOMELINE ALONE OR COMBINED WITH A MOOD STABILISING OR ANTIMANIC AGENT TO TREAT BIPOLAR DISORDERS | MINSTER RESEARCH LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067496-A1 | COMBINATION OF SABCOMELINE WITH A NEUROLEPTIC AGENT TO TREAT PSYCHOTIC DISORDERS | MINSTER RESEARCH LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067423-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067417-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| EP-1663248-A1 | 7-HETEROARYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2006-06-07 | — | — | EP | disclosed |
| US-20060110456-A1 | Method for biocidal and/or biostatic treatment and compositions therefor | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2006-05-25 | — | — | US | disclosed |
| WO-2006030300-A2 | PROCESSES FOR THE PREPARATION OF OLANZAPINE | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-23 | — | — | WO | disclosed |
| US-20060040920-A1 | Crystal forms of olanzapine and processes for their preparation | KRKA, D.D. NOVO MESTO (SI) | 2006-02-23 | — | — | US | disclosed |
| EP-1627639-A2 | Use of COX-2 inhibitors for the treatment of affective disorders | Müller, Norbert (DE) | 2006-02-22 | — | — | EP | disclosed |
| WO-2006013435-A1 | MIXED SOLVATE OF OLANZAPINE, METHOD FOR PREPARING IT AND METHOD FOR PREPARING FORM I OF OLANZAPINE THEREFROM | INKE, S.A. (ES) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006006185-A1 | IMPROVED PROCESS FOR MAKING FORM I OF OLANZAPINE. | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2006-01-19 | — | — | WO | disclosed |
| WO-2006002956-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-01-12 | — | — | WO | disclosed |
| EP-1611139-A1 | METHODS OF PREPARING OLANZAPINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005123192-A2 | IMPROVING PAIN TREATMENT WITH STRONTIUM COMBINATIONS | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
| CN-1233646-C | Process of 2-methyl-thiophene benzodinitro heterotropilidene | HWASHENG PHARMACEUTICAL CORP (US) | 2005-12-28 | — | — | CN | disclosed |
| CN-1233646-C | Process of 2-methyl-thiophene benzodinitro heterotropilidene | HWASHENG PHARMACEUTICAL CORP (US) | 2005-12-28 | — | — | CN | disclosed |
| WO-2005090359-A2 | SYNTHESIS OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2, 3-B][1,5]BENZODIAZEPINE AND SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005085256-A1 | ISOPROPANOL WATER SOLVATE OF OLANZAPINE | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2005-09-15 | — | — | WO | disclosed |
| US-20050192313-A1 | Substituted thioacetamides | CEPHALON, INC. (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050159408-A1 | Methods of synthesizing olanzapine | TEVA PHARMACEUTICALS USA, INC. | 2005-07-21 | — | — | US | disclosed |
| US-6919367-B2 | Substituted thioacetamides | CEPHALON, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| WO-2005063771-A1 | METHODS OF PREPARING OLANZAPINE | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2005-07-14 | — | — | WO | disclosed |
| EP-1551414-A2 | CRYSTAL FORMS OF OLANZAPINE AND PROCESSES FOR THEIR PREPARATION | KRKA, D.D., Novo Mesto (SI) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005051397-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051399-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051398-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051916-A1 | 7-[4-(4-CHLOROBENZYLOXY) BENZENESULFONYL]-8-METHOXY-3-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINIUM MALEATE OR TOSYLATE AS ANTIPSYCHOTICS | GLAXO GROUP LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005049034-A2 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005025576-A1 | 7-HETEROARYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005016891-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005014578-A1 | PHENYLSULFONYL COMPOUNDS AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005009407-A2 | ORAL PHARMACEUTICAL FORMULATIONS OF OLANZAPINE | RANBAXY LABORATORIES LIMITED (IN) | 2005-02-03 | — | — | WO | disclosed |
| US-20050008690-A1 | Supplying active materials in various phases in single dosage multicompartment capsule | INNERCAP TECHNOLOGIES, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004094390-A1 | 2-METHYL-THIENO-BENZODIAZEPINE PROCESS | WATSON PHARMACEUTICALS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094390-A1 | 2-METHYL-THIENO-BENZODIAZEPINE PROCESS | WATSON PHARMACEUTICALS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004089313-A2 | NOVEL OLANZAPINE FORMS AND RELATED METHODS OF TREATMENT | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204469-A1 | Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders | MULLER NORBERT | 2004-10-14 | — | — | US | disclosed |
| CN-1532199-A | Process of 2-methyl-thiophene benzodinitro heterotropilidene | 华生制药公司 | 2004-09-29 | — | — | CN | disclosed |
| CN-1532199-A | Process of 2-methyl-thiophene benzodinitro heterotropilidene | 华生制药公司 | 2004-09-29 | — | — | CN | disclosed |
| US-20040176357-A1 | 2 Methyl-thieno-benzodiazepine lyophilized formulation | DEKEMPER KURT DOUGLAS (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1438288-A1 | SUBSTITUTED THIOACETAMIDES | CEPHALON, INC. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040116445-A1 | Substituted thioacetamides | CEPHALON INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1423124-A2 | LYOPHILIZED FORMULATION COMPRISING OLANZAPINE | ELI LILLY AND COMPANY (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-1397145-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS | Müller, Norbert (DE) | 2004-03-17 | — | — | EP | disclosed |
| WO-2004006933-A2 | CRYSTAL FORMS OF OLANZAPINE AND PROCESSES FOR THEIR PREPARATION | KRKA, D.D., NOVO MESTO (SI) | 2004-01-22 | — | — | WO | disclosed |
| US-6670358-B2 | Substituted thioacetamides | CEPHALON, INC. | 2003-12-30 | — | — | US | disclosed |
| US-20030130334-A1 | Methods and compositions for the treatment of psychiatric disorders | MULLER NORBERT | 2003-07-10 | — | — | US | disclosed |
| CN-1429210-A | Substituted thioacetamides | CEPHALON INC (US) | 2003-07-09 | — | — | CN | disclosed |
| CN-1420117-A | Method for preparing olanzapine | HAOSEN PHARMACEUTICAL CO LTD L (CN) | 2003-05-28 | — | — | CN | disclosed |
| WO-2003037853-A1 | SUBSTITUTED THIOACETAMIDES | CEPHALON, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1292573-A2 | SUBSTITUTED THIOACETAMIDES | CEPHALON, INC. (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2003007912-A2 | LYOPHILIZED FORMULATION COMPRISING OLANZAPINE | ELI LILLY AND COMPANY (US) | 2003-01-30 | — | — | WO | disclosed |
| WO-2002102297-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS | MUELLER NORBERT (DE) | 2002-12-27 | — | — | WO | disclosed |
| US-6492396-B2 | Substituted thioacetamides | CEPHALON, INC. | 2002-12-10 | — | — | US | disclosed |
| US-20020183334-A1 | Substituted thioacetamides | CEPHALON, INC. | 2002-12-05 | — | — | US | disclosed |
| WO-2001058439-A9 | LOW DOSE MODAFINIL FOR ENHANCEMENT OF COGNITIVE FUNCTION | CEPHALON INC (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020045629-A1 | Substituted thioacetamides | CEPHALON, INC. | 2002-04-18 | — | — | US | disclosed |
| WO-2001087830-A2 | SUBSTITUTED THIOACETAMIDES | CEPHALON, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
| US-20010034373-A1 | Low dose modafinil for enhancement of cognitive function | CEPHALON, INC. | 2001-10-25 | — | — | US | disclosed |
| WO-2001058439-A1 | LOW DOSE MODAFINIL FOR ENHANCEMENT OF COGNITIVE FUNCTION | CEPHALON, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| EP-0582368-B1 | Thienobenzodiazepine derivatives for treatment of CNS disorders | LILLY CO ELI (GB) | 2001-01-24 | — | — | EP | disclosed |
| EP-0582368-B1 | Thienobenzodiazepine derivatives for treatment of CNS disorders | LILLY CO ELI (GB) | 2001-01-24 | — | — | EP | disclosed |
| US-6034078-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 2000-03-07 | — | — | US | disclosed |
| US-6034078-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 2000-03-07 | — | — | US | disclosed |
| US-6008216-A | CHEMICAL SYNTHESIS OF ANTIPSYCHOTIC DRUGS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM, SERIOUS MENTAL CONDITIONS SUCH AS PSYCHOSIS, SCHIZOPHRENIA AND SCHIZOPHRENIFORM ILLNESSES | ELI LILLY AND COMPANY AND LIMITED (GB) | 1999-12-28 | — | — | US | disclosed |
| CN-1043994-C | Thienobenzodiazepine compound and preparation method and application thereof | LILLY INDUSTRIES LTD (GB) | 1999-07-07 | — | — | CN | disclosed |
| US-5817655-A | TREATMENT OF NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1998-10-06 | — | — | US | disclosed |
| US-5817655-A | TREATMENT OF NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1998-10-06 | — | — | US | disclosed |
| US-5817657-A | USING 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO(2,3-B)(1,5)BENZ ODIAZEPINE | ELI LILLY AND COMPANY (US) | 1998-10-06 | — | — | US | disclosed |
| US-5817656-A | 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO(2,3-B)(1,5)BENZ ODIAZEPINE | ELI LILLY AND COMPANY (US) | 1998-10-06 | — | — | US | disclosed |
| US-5627178-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | LILLY INDUSTRIES LIMITED (GB) | 1997-05-06 | — | — | US | disclosed |
| US-5605897-A | NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0454436-B1 | Pharmaceutical compounds | LILLY INDUSTRIES LTD (GB) | 1995-09-13 | — | — | EP | disclosed |
| CN-1028429-C | Method for preparing thienobenzodiazepine compound | LILLY INDUSTRIES LTD (GB) | 1995-05-17 | — | — | CN | disclosed |
| EP-0354781-B1 | Benzodiazepine compounds and their use as pharmaceuticals | LILLY INDUSTRIES LTD (GB) | 1994-11-02 | — | — | EP | disclosed |
| CN-1025857-C | Process for preparing thiazolo [5, 4-b ] [1, 5] benzodiazepines having pharmacological properties | LILLY INDUSTRIES LTD (GB) | 1994-09-07 | — | — | CN | disclosed |
| CN-1085903-A | Medical compounds | LILLY INDUSTRIES LTD (GB) | 1994-04-27 | — | — | CN | disclosed |
| EP-0582368-A1 | Thienobenzodiazepine derivatives for treatment of CNS disorders | LILLY INDUSTRIES LIMITED (GB) | 1994-02-09 | — | — | EP | disclosed |
| EP-0582368-A1 | Thienobenzodiazepine derivatives for treatment of CNS disorders | LILLY INDUSTRIES LIMITED (GB) | 1994-02-09 | — | — | EP | disclosed |
| US-5229382-A | Treating disorders of the central nervous system including psychosis, acute mania, anxiety, or schizophrenia | LILLY INDUSTRIES LIMITED (GB) | 1993-07-20 | — | — | US | disclosed |
| CN-1056693-A | Medical compounds | LILLY INDUSTRIES LTD (GB) | 1991-12-04 | — | — | CN | disclosed |
| EP-0454436-A1 | Pharmaceutical compounds | LILLY INDUSTRIES LIMITED (GB) | 1991-10-30 | — | — | EP | disclosed |
| US-5051516-A | Chemical intermediates for central nervous system active drug s | LILLY INDUSTRIES LIMITED (GB) | 1991-09-24 | — | — | US | disclosed |
| US-4977150-A | Neuroleptic agents | LILLY INDUSTRIES LIMITED (GB) | 1990-12-11 | — | — | US | disclosed |
| CN-1040798-A | Benzodiazepines compound and preparation method thereof and the application on medicine | LILLY INDUSTRIES LTD (GB) | 1990-03-28 | — | — | CN | disclosed |
| EP-0354781-A2 | Benzodiazepine compounds and their use as pharmaceuticals | LILLY INDUSTRIES LIMITED (GB) | 1990-02-14 | — | — | EP | disclosed |
| EP-0086981-B1 | SUBSTITUTED THIENOBENZODIAZEPINONES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1986-09-10 | — | — | EP | disclosed |
| US-4424225-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-01-03 | — | — | US | disclosed |
| EP-0086982-A1 | Substituted thienobenzodiazepinones, process for preparing them and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1983-08-31 | — | — | EP | disclosed |
| EP-0086981-A1 | Substituted thienobenzodiazepinones, process for their preparation and medicines containing these compounds | Dr. Karl Thomae GmbH (DE) | 1983-08-31 | — | — | EP | disclosed |
| US-4381301-A | Substituted tricyclic thieno compounds, their synthesis, their use, their compositions and their medicaments | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1983-04-26 | — | — | US | disclosed |
| US-4172831-A | CENTRAL NERVOUS SYSTEM | LILLY INDUSTRIES LIMITED (GB) | 1979-10-30 | — | — | US | disclosed |
| US-4168269-A | ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1979-09-18 | — | — | US | disclosed |
| US-4168269-A | ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1979-09-18 | — | — | US | disclosed |